Advanced Accelerator Applications - 2025 Company Profile, Funding & Competitors

Company Details

Advanced Accelerator Applications, a Novartis company, (acquired for $3.9B in October 2017) develops, manufactures and markets radiopharmaceuticals for diagnostic and therapeutic applications in the fields of oncology, neurology, cardiology and infectious & inflammatory diseases. It is a spin-off of the 鈥淓uropean Organization for Nuclear Research鈥� (CERN), Geneva, Switzerland. The company primarily makes PET and SPECT tracers for diagnosing a range of diseases and disorders. The company's lead candidate Lutathera (lutetium Lu 177 dotatate) has been approved by the US FDA for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults and as per company claims is the first available FDA approved Peptide Receptor Radionuclide Therapy (PRRT).

Key Metrics

Founded Year

2002

Location

Saint Genis Pouilly, France

Stage

Acquired

Total Funding

in 2 rounds

Latest Funding Round

Investors

Vivo Capital & 5 more

Ranked

1^st among 49 active competitors

Annual Revenue

as on Dec 31, 2023

Investment & Acquisitions

Similar Companies

ITM &

Exit Details

Acquired by Novartis (Oct 30, 2017)

Legal entities associated with Advanced Accelerator Applications

Advanced Accelerator Applications is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Jul 12, 2019	$235M (as on Dec 31, 2023)	729	536

Advanced Accelerator Applications got acquired by Novartis on Oct 30, 2017 at an acquisition amount of $3.9B. It was facilitated by Jefferies and PJT Partners.

Click to take a look at Advanced Accelerator Applications's acquisition in detail

Advanced Accelerator Applications has raised a total funding of $56.1M over 2 rounds. Its first funding round was on Feb 17, 2014.

Advanced Accelerator Applications has 6 institutional investors including , HBM Partners and .

Here is the list of recent funding rounds of Advanced Accelerator Applications:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Apr 01, 2015	$283K	Grant (prize money)	5205403	9934845	-
Feb 17, 2014	$56.1M	Series B	1069467	9934399	HBM Partners

Access funding benchmarks and valuations. Sign up today!

View details of Advanced Accelerator Applications's funding rounds and investors

The founders of Advanced Accelerator Applications is Stefano Buono. Stefano Buono is the CEO of Advanced Accelerator Applications. Stefano Buono has founded 2 more companies - Elysia Capital and Newcleo.

View details of Advanced Accelerator Applications's Founder profiles and Board Members

Top competitors of Advanced Accelerator Applications include ITM, SOFIE and Mariana Oncology. Here is the list of Top 10 competitors of Advanced Accelerator Applications, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, HBM Partners听&补尘辫;听	77/100
2nd	ITM 2004, Munich (Germany), Series E	Developer of radiopharmaceuticals and radioisotopes for cancer treatment	$681M	Temasek, BlackRock听&补尘辫;听	66/100
3rd	SOFIE 2008, Culver City (United States), Series C	Developer of molecular imaging systems and radio-pharmaceuticals	$38.1M	, Trilantic Capital Partners North America听&补尘辫;听	66/100
4th	Mariana Oncology 2020, Watertown (United States), Acquired	Developer of radiopharmaceuticals for solid tumors	$250M	Atlas Venture, RA Capital Management听&补尘辫;听	63/100
5th	AdvanCell 2019, Sydney (Australia), Series C	Radiopharmaceutical company developing targeted alpha therapies for cancer treatment	$129M	Abingworth, SV Health Investors听&补尘辫;听	63/100
6th	Ariceum Therapeutics 2021, Berlin (Germany), Series A	Developer of drugs for systemic targeted radiation therapy to treat cancer	$51.6M	EQT, Healthcap听&补尘辫;听	62/100
7th	Lantheus 2008, Billerica (United States), Public	Developer of diagnostic imaging agents and targeted therapeutics	-	HealthCare Royalty Partners	62/100
8th	Alpha-9 Oncology 2018, Boston (United States), Series C	Developer of radiopharmaceuticals for the treatment of cancer	$261M	RA Capital Management, Janus Henderson Investors听&补尘辫;听	59/100
9th	ARTBIO 2021, Sacramento (United States), Series A	Develoer of alpha radioligand therapies for cancer treatment	$113M	Omega Funds, F-Prime Capital听&补尘辫;听	59/100
10th	PanTera 2022, Mol (Belgium), Series A	Developer of radiotheranostics that facilitates life-enhancing treatments for patients	$148M	EQT, Eurazeo听&补尘辫;听	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Advanced Accelerator Applications's competitors? Click to see the top ones

Advanced Accelerator Applications has acquired 3 companies including , and Atreus Pharmaceuticals. Advanced Accelerator Applications has not made any investments as of now. Here is the list of its acquisitions: